Follow-up of women with gestational diabetes and later type 2 diabetes
Follows women with gestational diabetes to see if insulin problems predict type 2 diabetes.
Key facts
- Who runs it
- University Hospital Tuebingen
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Gestational Diabetes
- Status
- Recruiting
- People taking part
- 800 people, planned
- Started
- 23 May 2012
- Expected to end
- 1 May 2028
- Type of study
- Observational, 2 groups
- Record updated
- 22 August 2022
Who can take part
The trial is looking for women during pregnancy, or after a pregnancy with gestational diabetes (high blood sugar first found in pregnancy). Women with and without gestational diabetes can join.
- Age
- 18 years and older
- Sex
- Women only
- Disease stage
- Pregnant women can join in pregnancy weeks 24+0 to 31+6. Women after birth can join if gestational diabetes was documented in a previous pregnancy.
- Earlier treatment
- People taking drugs that raise or lower blood sugar, such as steroids, antidiabetics or insulin, cannot join.
- Main reasons for not taking part
- Type 1 or type 2 diabetes
- Kidney function (GFR) below 60 ml/min/1,73 m2, CRP above 1 mg/dl, or liver enzymes (transaminases) more than 2 fold above the upper normal limit
- Existing heart conditions or psychiatric disorders
- Weight loss of more than 10% in the 6 months before joining, or chronic alcohol or drug abuse
- For visits after birth only: being pregnant or breastfeeding
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Signed and dated informed consent; Enrollment is possible during AND after gestation:
- Baseline visit (pregnancy): gestational week 24+0 till 31+6
- Postpartum visits: documented occurence of GDM in previous pregnancy
Who cannot take part
- Weight loss > 10% within 6 months prior to inclusion
- Blood sugar increasing or decreasing drug therapy, e.g. steroids, antidiabetics, insulin
- Diabetes Mellitus Type 1 or Type 2
- Preexisting cardiac conditions
- Psychiatric disorders
- GFR < 60 ml/min/1,73 m2
- CRP > 1 mg/dl
- Increased levels of transaminases 2 fold above ULN
- Age < 18years
- Chronic alcohol or substance abuse
- only postpartum visits: pregnancy or lactation
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sex
- Gestational diabetes
This trial is currently available in Germany.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Due to a changed lifestyle with less physical activity, unfavorable diets rich in fat and calories and obesity, the prevalence of diabetes mellitus is increasing worldwide. The diabetes epidemic is associated with significant personal and socio-economic consequences. Despite attempts to prevent the complications of diabetes, this disease is still the leading cause of blindness, chronic renal insufficiency and non-traumatic amputation. It is important to detect early on an increase in blood sugar and treat it accordingly to reduce costs and to minimize the personal suffering of those affected. As the number of patients with type 2 diabetes mellitus continues to rise, the number of young women with gestational diabetes mellitus (GDM) also increases. This is a disorder og glucose metabolism, which occurs for the first time in pregnancy. The causes for this are manifold. Among other causes, the increasing age of the mothers and weight gain during pregnancy are risk factors for gestational diabetes. Although it has been recommended that women with gestational diabetes should be re-examined after the birth of their child, many women have not. The study is a follow-up study to clarify whether insulin secretion disorder in women with and after GDM is a risk factor for the occurrence of type 2 diabetes mellitus.
The 2 groups in the trial
- Women with GDM
- Women without GDM
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- German Study Gestational Diabetes (PREG)
- Plain-language title
- Follow-up of women with gestational diabetes and later type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT04270578, who can take part
- Publications
- Incretin Hypersecretion in Gestational Diabetes Mellitus.The Journal of clinical endocrinology and metabolism, 2022
- The German Gestational Diabetes Study (PREG), a prospective multicentre cohort study: rationale, methodology and design.BMJ open, 2022
- Pre-pregnancy BMI but not mild stress directly influences Interleukin-6 levels and insulin sensitivity during late pregnancy.Frontiers in bioscience (Landmark edition), 2022
- Record updated
- 22 August 2022